Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fexapotide - Nymox Pharmaceutical

Drug Profile

Fexapotide - Nymox Pharmaceutical

Alternative Names: Fexapotide triflutate; NX-1207; REC-0482

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nymox Pharmaceutical Corporation
  • Developer Nymox Pharmaceutical Corporation; Recordati
  • Class Antineoplastics; Proteins
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Benign prostatic hyperplasia
  • Phase III Prostate cancer
  • Discontinued Liver cancer

Most Recent Events

  • 09 Oct 2018 Updated long-term efficacy data from the phase IIb NX03-0040 trial in Prostate cancer released by Nymox Pharmaceutical
  • 03 Oct 2018 Phase-III clinical trials in Prostate cancer in USA (Intraprostatic)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top